Which drug produces little change in systemic vascular resistance, but at low or intermediate doses increases renal blood flow while at high doses decreases it?

Which drug produces little change in systemic vascular resistance, but at low or intermediate doses increases renal blood flow while at high doses decreases it?

• A. Dopamine
• B. Norepinephrine
• C. Epinephrine
• D. Isoproterenol

Answer: (A)

The key idea is that dopamine acts in a dose-dependent way on different receptors to change renal blood flow and systemic vascular resistance. At very low doses, dopamine preferentially stimulates D1 receptors in the renal vasculature, causing vasodilation of the renal arteries. This increases renal blood flow (and urine output) with little to no change in systemic vascular resistance. As the dose increases to an intermediate range, dopamine also activates beta-1 receptors, boosting heart rate and contractility and raising cardiac output, which can support renal perfusion further without causing a big shift in vascular resistance. When the dose is high, alpha-1 receptor effects predominate, leading to systemic vasoconstriction and an increase in systemic vascular resistance; this vasoconstriction reduces renal blood flow. That combination—renal vasodilation with little SVR change at low doses, preserved or enhanced renal flow with intermediate doses, and reduced renal flow with high doses due to vasoconstriction—fits dopamine best. The other drugs don’t match this specific pattern: norepinephrine and epinephrine tend to raise systemic vascular resistance with less renal-specific vasodilation, and isoproterenol mainly causes beta-mediated vasodilation with a drop in SVR, not the described rise-and-fall pattern in renal perfusion.

The key idea is that dopamine acts in a dose-dependent way on different receptors to change renal blood flow and systemic vascular resistance. At very low doses, dopamine preferentially stimulates D1 receptors in the renal vasculature, causing vasodilation of the renal arteries. This increases renal blood flow (and urine output) with little to no change in systemic vascular resistance. As the dose increases to an intermediate range, dopamine also activates beta-1 receptors, boosting heart rate and contractility and raising cardiac output, which can support renal perfusion further without causing a big shift in vascular resistance. When the dose is high, alpha-1 receptor effects predominate, leading to systemic vasoconstriction and an increase in systemic vascular resistance; this vasoconstriction reduces renal blood flow.

That combination—renal vasodilation with little SVR change at low doses, preserved or enhanced renal flow with intermediate doses, and reduced renal flow with high doses due to vasoconstriction—fits dopamine best. The other drugs don’t match this specific pattern: norepinephrine and epinephrine tend to raise systemic vascular resistance with less renal-specific vasodilation, and isoproterenol mainly causes beta-mediated vasodilation with a drop in SVR, not the described rise-and-fall pattern in renal perfusion.